Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mereo Biopharma Group Plc ADR (NQ: MREO ) 4.280 +0.070 (+1.66%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Mereo Biopharma Group Plc ADR < Previous 1 2 Next > Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference September 12, 2024 From Mereo BioPharma Group plc Via GlobeNewswire Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update August 13, 2024 From Mereo BioPharma Group plc Via GlobeNewswire Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market June 14, 2024 From Mereo BioPharma Group plc Via GlobeNewswire Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI) June 11, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference May 30, 2024 From Mereo BioPharma Group plc Via GlobeNewswire Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update May 15, 2024 From Mereo BioPharma Group plc Via GlobeNewswire Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference April 03, 2024 From Mereo BioPharma Group plc Via GlobeNewswire Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update March 27, 2024 From Mereo BioPharma Group plc Via GlobeNewswire Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference March 05, 2024 From Mereo BioPharma Group plc Via GlobeNewswire Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments January 08, 2024 From Mereo BioPharma Group plc Via GlobeNewswire Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update October 23, 2023 From Mereo BioPharma Group plc Via GlobeNewswire Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI) October 14, 2023 From Ultragenyx Pharmaceutical Inc.; Mereo Biopharma Via GlobeNewswire Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI) October 09, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference September 21, 2023 From Mereo BioPharma Group plc Via GlobeNewswire Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update September 07, 2023 From Mereo BioPharma Group plc Via GlobeNewswire Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) July 06, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Mereo BioPharma to Present at the Jefferies Healthcare Conference May 31, 2023 From Mereo BioPharma Group plc Via GlobeNewswire Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma’s Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference May 23, 2023 From Mereo BioPharma Group plc Via GlobeNewswire Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement May 08, 2023 From Mereo BioPharma Group plc Via GlobeNewswire Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market May 05, 2023 From Mereo BioPharma Group plc Via GlobeNewswire Mereo BioPharma to Participate in Fireside Chat at the 22nd Annual Needham Healthcare Conference April 13, 2023 From Mereo BioPharma Group plc Via GlobeNewswire Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights March 28, 2023 From Mereo BioPharma Group plc Via GlobeNewswire Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease March 21, 2023 From Mereo BioPharma Group plc Via GlobeNewswire Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference February 08, 2023 From Mereo BioPharma Group plc Via GlobeNewswire Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference November 08, 2022 From Mereo BioPharma Group plc Via GlobeNewswire Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency November 02, 2022 From Mereo BioPharma Group plc Via GlobeNewswire Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management October 28, 2022 From Mereo BioPharma Group plc Via GlobeNewswire Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022 October 24, 2022 From Mereo BioPharma Group plc Via GlobeNewswire Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting October 21, 2022 From Mereo BioPharma Group plc Via GlobeNewswire Rubric Capital Management Comments on Mereo BioPharma Updated Operating Plan October 18, 2022 From Rubric Capital Management LP Via Business Wire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
